Optimising Translational Testing, Neoantigen Validation, & Novel Therapies to Streamline Clinical Trials & Develop Durable Neoantigen-Targeted Therapies with High Immune Response & Clinical Efficacy
The neoantigen-targeted therapies industry is thawing and coming out of its biotech winter fuelled by Moderna’s recent news showing 49% decrease in disease progression after 5 years. This momentum has reignited confidence across pharma and biotech, accelerating a neoantigen programme and pushing more candidates into the clinic than ever before.
The 9th International Neoantigen Summit returns to Amsterdam to bring together the only dedicated forum for end-end neoantigen development. From validation and identification to clinical readouts, biomarker strategy, personalised and off-the-shelf approaches – this is your only platform dedicated to sharing critical developments in neoantigen therapies.
In a unique position to unite all the key players in the neoantigen industry, including the likes of Nykode Therapeutics, Evaxion, Geneos and more, this summit sits at the heart of the neoantigen industry, making every conversation relevant and every connection intentional.
Attend your only annual checkpoint to access the latest clinical updates, uncover breakthrough innovations and form partnerships that will drive the next wave of neoantigen-targeted therapies forward.
Very relevant presentations, lots of new clinical data. Good opportunities to reconnect with other attendees.
Infinitopes
I was great to get updates about latest neoantigen therapeutic programmes and to get in touch with colleagues from different countries.
Andarix Pharmaceutical
Great speaker list and actual topics in the field are addressed. Room for great discussions: after session discussions but also panels and round tables. The audience has a nice size so that it is easy to connect.
Evaxion Biotech
Explore the Full Event Guide
- Accelerating precision immunotherapy by combining bioinformatics and AI to solve neoantigen validation bottlenecks, with insights from Khosen Bio and Transgene
- Enhancing personalised cancer vaccines through real‑world clinical learnings from Evaxion’s AI‑driven neoantigen immunotherapy platform
- Advancing DNA‑encoded neoantigen vaccines to drive robust immune responses in advanced cancer patients, featuring Nykode Therapeutics
- Unlocking the dark genome to discover novel targets for affordable, multi‑valent cancer immunotherapies, with Epitopea
- Scaling personalised neoantigen peptide immunotherapy for glioblastoma by optimising development and manufacturing pathways, with YGION Biomedical
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions